Relatively short term (2–4 weeks) treatment with CSF1R inhibitors results in a significant depletion of Ly6Clow monocytes (equivalent to human non-classical CD16+ monocytes) and M2-polarized tissue and tumour-associated macrophage subpopulations that express CSF1R at higher levels. Here, CSF1R is linked to neoplasm.